Calidi Biotherapeutics Inc. Featured for Breakthrough Cancer Treatment Platform
July 8th, 2025 2:49 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc.'s innovative genetic medicine platform, targeting cancer with engineered viruses, is highlighted as a potential game-changer in oncology.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in an editorial discussing its precision genetic medicine platform, which utilizes engineered viruses to target both primary and metastatic cancer tumors. With projections indicating that global cancer diagnoses could reach 35 million annually by 2050, Calidi's technology presents a promising avenue for addressing significant unmet needs in cancer treatment. The platform's ability to deliver potent genetic therapies directly to cancer sites offers a novel approach that could revolutionize the fight against cancer.
The company's clinical-stage immuno-oncology technology leverages proprietary stem cell-based platforms to carry oncolytic viruses, aiming to enhance efficacy and improve patient safety in treating high-grade gliomas and solid tumors. This innovative strategy not only targets existing tumors but also holds the potential to prevent metastatic disease, marking a significant advancement in cancer therapy. For more information on Calidi Biotherapeutics and its groundbreaking work, visit https://www.calidibio.com.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
